Table 4.

Clinical signs at initial diagnosis, presumed first relapse and during cyclophosphamide therapy in cats with relapsed low-grade alimentary lymphoma (LGAL) receiving rescue cyclophosphamide after failing chlorambucil treatment

Clinical sign	At initial diagnosis, n (n = 20 total*)				At first presumed relapse, n (n = 16 total † )				During cyclophosphamide therapy, n (n = 20 total ‡ )
	Grade 1 or 2	Grade 3 or 4	Grade unknown	Total	Grade 1 or 2	Grade 3 or 4	Grade unknown	Total	Grade 1 or 2	Grade 3 or 4	Grade unknown	Total
Weight loss §	0	0	15	15	9	1	0	10	5	4	0	9 ¶
Anorexia	1	0	6	7	3	1	0	4	13	1	2	16
Vomiting	5	2	3	10	6	1	0	7	9	0	0	9
Diarrhea	5	1	2	8	6	0	0	6	7	0	0	7
Lethargy	2	1	2	5	2	1	0	3	4	1	2	7
Dehydration	2	0	0	2	1	0	0	1	1	1	0	2
Fever	1	0	0	1	0	0	0	0	0	0	0	0
Ascites	0	0	0	0	0	0	0	0	1	0	0	1
Number of clinical signs				n				n				n
0				0				1				0
1				8				5				5
2				2				5				5
3				7				4				6
>3				3				1				4

^*Clinical signs were recorded from a physical examination performed at the time of initial diagnosis

^†Clinical signs were recorded from a physical examination performed at the time of first presumed relapse (ie, start of cyclophosphamide treatment)

^‡Clinical signs were recorded at various time points throughout cyclophosphamide therapy at the discretion of the specific overseeing clinician

^§The comparator for weight loss was the weight noted at the previous time point. For the initial diagnosis, the comparator was from a previous weight that was not necessarily dated. At first presumed relapse (the start of cyclophosphamide therapy), the comparator weight was from initial diagnosis. During cyclophosphamide therapy, the baseline weight was from the start of cyclophosphamide therapy and was compared with the lowest documented weight during cyclophosphamide therapy

^¶In three of these cats, weight gain was also noted during cyclophosphamide therapy